Literature DB >> 8361757

H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.

A Cuadrado1, J T Bruder, M A Heidaran, H App, U R Rapp, S A Aaronson.   

Abstract

We examined the effect of overexpression of growth factor-regulated second messenger enzymes, alone and in combination, on transformation of NIH3T3 cells. Signal transducers included phospholipase C-gamma (PLC-gamma), protein kinase C-gamma (PKC-gamma), and two proto-oncogenes, c-H-ras and c-raf-1. Three of these proteins, PLC-gamma, PKC-gamma and Raf-1, did not transform NIH3T3 cells alone or in combination. c-H-ras, which under its own promoter control has low transforming activity, also did not cooperate with PLC-gamma or PKC-gamma. In contrast, the combination of normal or oncogenic p21 H-Ras with the Raf-1 kinase dramatically increased transformation efficiency. The level of Ras protein required for transformation was reduced in Raf-1 co-transfectants, implying that, at low levels of p21 Ras, p74 Raf-1 is rate limiting. As transformation by Ras depends on jun-mediated transcriptional events, we also examined H-ras and c-raf-1 cooperation in transcriptional transactivation of TPA-responsive element (TRE)-dependent reporters. Like the H-ras/c-raf-1 cooperation in transformation, we observed this synergistic stimulation of TRE-dependent transcription. This pathway for transformation and transcriptional activation by increased levels of normal Ras and Raf may be important in tumors that show overexpression but lack mutationally activated forms of these two proto-oncogenes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8361757

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Protein kinases as therapeutic targets.

Authors:  R Sridhar; O Hanson-Painton; D R Cooper
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation.

Authors:  David Wan-Cheng Li; Jin-Ping Liu; Ying-Wei Mao; Hua Xiang; Juan Wang; Wei-Ya Ma; Zigang Dong; Helen M Pike; Rhoderick E Brown; John C Reed
Journal:  Mol Biol Cell       Date:  2005-07-06       Impact factor: 4.138

3.  Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase.

Authors:  H Cai; U Smola; V Wixler; I Eisenmann-Tappe; M T Diaz-Meco; J Moscat; U Rapp; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

4.  Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals.

Authors:  W M Yee; P F Worley
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

5.  Therapeutic strategies for targeting ras proteins.

Authors:  Stephan Gysin; Megan Salt; Amy Young; Frank McCormick
Journal:  Genes Cancer       Date:  2011-03

Review 6.  Raf kinases: function, regulation and role in human cancer.

Authors:  Deborah T Leicht; Vitaly Balan; Alexander Kaplun; Vinita Singh-Gupta; Ludmila Kaplun; Melissa Dobson; Guri Tzivion
Journal:  Biochim Biophys Acta       Date:  2007-05-22

7.  Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages.

Authors:  D Büscher; R A Hipskind; S Krautwald; T Reimann; M Baccarini
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

8.  Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal transduction.

Authors:  H Cai; P Erhardt; J Troppmair; M T Diaz-Meco; G Sithanandam; U R Rapp; J Moscat; G M Cooper
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

9.  Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells.

Authors:  Tariq Hamid; Mohammed T Malik; Sham S Kakar
Journal:  Mol Cancer       Date:  2005-01-13       Impact factor: 27.401

Review 10.  Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.

Authors:  Amelia Kellar; Cay Egan; Don Morris
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.